OncoNano Medicine Inc.

OncoNano Medicine is developing a new class of products that exploit universal cancer and immune therapeutic targets to diagnose and treat cancer. Our product candidates are designed to help patients across the continuum of cancer care and include solid tumor therapeutics, agents for real-time image-guided surgery, and T cell activating immunotherapies.

Our core technology is comprised of ultra pH-sensitive polymeric micelles that have been engineered to encapsulate and protect a wide variety of payloads, and selectively release them upon exposure to acidic biological environments within tumors and endosomes. Imaging and therapeutic payloads can be encapsulated
in the micelles for systemic administration to specifically target the acidic tumor microenvironment – a hallmark of all solid tumors (the Warburg effect) – while minimizing exposure to normal tissues. Use of pH as a biomarker for cancer
enables micelles to be applied generally to any solid tumor, regardless of its oncogenic phenotype and has been demonstrated in numerous in vivo models and in patients.

In addition to therapeutic delivery, proprietary micelle compositions are developed to activate Stimulator of Interferon Genes (STING), a ubiquitous immune signaling molecule for T cell therapy of solid tumors. Non-canonical STING activation is achieved through polyvalency in an unprecedented and advantageous manner. The combination of the natural STING ligand cGAMP with STING-activating polymers further synergizes innate immune activation leading to highly efficacious T cell immunity against solid cancers.

Key to the success of OncoNano’s polymeric micelle technology is the molecular cooperativity design that achieves threshold pH sensing and STING activation, thereby enabling high specificity in tumor targeting not possible with conventional therapeutic and imaging approaches.

Management Team

Martin Driscoll

Chief Executive Officer

Read Bio

Matthew Head, MBA

Chief Financial Officer

Read Bio

Don Kruppa, MBA

Vice President, Operations

Read Bio

Kathy Rath

Vice President, Regulatory Affairs

Read Bio

Brian Ostrander, MS

Vice President, Head of Clinical Operations

Read Bio

Tian Zhao, PhD

Senior Director, Research and Development

Read Bio

Keith Hall, PhD

Senior Director, Corporate Strategy

Read Bio

Ruolan Han, PhD

Vice President,
Nonclinical and Translational Medicine

Read Bio

Prof. Jinming Gao, PhD

Co-Founder & Chief Scientific Officer

Read Bio

Board of Directors

Al Guillem, PhD

Chairman of the Board,
CEO of Renibus Therapeutics

Martin Driscoll

Chief Executive Officer

John Dyett

Co-Founder and Managing Director,
Salem Partners, LLC

Joydeep Goswami, PhD

SVP, Chief Strategy and Corporate Development Officer, Illumina

Yumin Qiu, CFA, CMA

Partner, Healthcare Investment,
Advantech Capital

Scientific Advisory Board

Prof. Charles Balch, MD

Read Bio

John Niederhuber, MD

Read Bio

Raphael Pollock, MD, PhD

Read Bio

Paul Bunn, MD

Read Bio

Prof. Alexander Eggermont, PhD, MD

Read Bio

Prof. Baran Sumer, MD

Co-Founder

Read Bio

Prof. Jinming Gao, PhD

Co-Founder & Chief Scientific Officer

Read Bio